Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor-Reference-Cited by-同舟云学术

Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor

Published:2019-08-15 Issue:5 Volume:81 Page:585-593
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Asundi Archana,Robles Yvonne,Starr Tyler,Landay Alan,Kinslow Jennifer,Ladner Joshua,White Laura,Plank Rebeca M.,Melbourne Kathleen,Weisholtz Daniel,Bennett Monica,Pan Hong,Stern Emily,Lin Alexander,Kuritzkes Daniel R.,Lin Nina H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference53 articles.

1. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK;Rockstroh;J Acquir Immune Defic Syndr.,2013

2. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med.,2013

3. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients;Ma;J Neurovirol.,2016

4. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals;Scourfield;AIDS.,2012

5. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring;Gutierrez;Clin Infect Dis.,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial;Infectious Diseases and Therapy;2024-04-20

2. Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen;eBioMedicine;2024-04

3. Efficacy and safety of raltegravir plus lamivudine maintenance therapy;Journal of Antimicrobial Chemotherapy;2023-12-01

4. Integrase inhibitors: current protagonists in antiretroviral therapy;Immunotherapy;2023-12

5. Immunological inefficiency of art in HIV-infected patients;HIV Infection and Immunosuppressive Disorders;2023-07-20